Description
| NO. | Product Name | Indications | Pharmacopeia | DMF | GMP |
|---|
| 1 | Zoledronic Acid | Anti-tumor | - | available | NMPA (Y20190000048) |
| 2 | Anastrazole | Anti-tumor | - | available | NMPA (Y20180001226) |
| 3 | Irinotecan hydrochloride | Anti-tumor | - | available | NMPA (Y20170001143) |
| 4 | Carmustine | Anti-tumor | - | available | NMPA (Y20190000412) |
| 5 | Clofarabine | Anti-tumor | - | available | NMPA (Y20190000716) |
| 6 | Thiotepa | Anti-tumor | - | available | NMPA (Y20190000642) |
| 7 | Pomalidomide Form A | Anti-tumor | - | available | NMPA (Y20190000475) |
| 8 | Imatinib Mesylate Beta | Anti-tumor | - | available | NMPA (Y20180001570) |
| 9 | Imatinib Mesylate | Anti-tumor | - | available | NMPA (Y20170000500) |
| 10 | Gefitinib | Anti-tumor | - | available | NMPA (Y20170001213) |
| 11 | Erlotinib Hydrochloride | Anti-tumor | - | available | NMPA (Y20190021519) |
| 12 | Carfilzomib | Anti-tumor | - | available | NMPA (Y20190000413) |
| 13 | Cabazitaxel | Anti-tumor | - | available | NMPA (Y20200000296) |
| 14 | Bortezomib | Anti-tumor | - | available | NMPA (Y20180001291) |
